Safety of jakinibs: lessons from ORAL Surveillance
Rheumatology (Oxford)
.
2022 Nov 2;61(11):4223-4225.
doi: 10.1093/rheumatology/keac166.
Authors
Marwan Bukhari
1
,
Martin Bergman
2
,
Jon T Giles
3
,
Carlos Lozada
4
,
John Cush
5
6
,
Kunihiro Yamaoka
7
,
Catriona McKay
8
,
Arthur Kavanaugh
9
Affiliations
1
Department of Rheumatology, University Hospitals of Morecambe Bay NHS Foundation Trust, Royal Lancaster Infirmary, Lancaster, UK.
2
Clinical Professor of Medicine, Drexel University College of Medicine, Philadelphia, PA.
3
Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY.
4
Division of Rheumatology and Immunology, University of Miami Miller School of Medicine, Miami, FL.
5
Department of Rheumatology, RheumNow, Dallas, TX, USA.
6
Department of Rheumatology, St George's University School of Medicine, Grenada, West Indies.
7
Department of Rheumatology, Kitasato University School of Medicine, Sagamihara, Japan.
8
Department of Rheumatology, McKay Morley Medical, Brighton, UK.
9
Department of Rheumatology, University of California San Diego, San Diego, CA, USA.
PMID:
35323916
DOI:
10.1093/rheumatology/keac166
No abstract available
Publication types
Editorial
MeSH terms
Humans
Janus Kinase Inhibitors*
Janus Kinases
Substances
Janus Kinase Inhibitors
Janus Kinases